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Abstract: Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy 
arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the 
peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. 
Histologically, the majority of ICCs are adenocarcinomas. Only a minority of patients (15%) 
present with resectable disease, with a median survival of less than 3 years. Multidisciplinary 
management of ICC is complicated by large differences in disease course for individual patients 
both across and within tumor stages. Risk models and nomograms have been developed to more 
accurately predict survival of individual patients based on clinical parameters. Predictive risk 
factors are necessary to improve patient selection for systemic treatments. Molecular differences 
between tumors, such as in the epidermal growth factor receptor status, are promising, but their 
clinical applicability should be validated. For patients with locally advanced disease, several 
treatment strategies are being evaluated. Both hepatic arterial infusion chemotherapy with 
floxuridine and yttrium-90 embolization aim to downstage locally advanced ICC. Selected 
patients have resectable disease after downstaging, and other patients might benefit because of 
postponing widespread dissemination and biliary obstruction.
Keywords: intrahepatic cholangiocarcinoma, diagnosis, treatment, developments
Incidence and risk factors
The incidence of intrahepatic cholangiocarcinoma (ICC) in the Western world is 
approximately one to two per 100,000.1–3 ICC is the second most common malignancy 
arising from the liver, accounting for 3% of all cases of gastrointestinal cancer.4,5 ICC 
makes up about 10% of all cholangiocarcinomas. It arises in peripheral bile ducts 
within the liver parenchyma, proximal to the secondary biliary radicals (Figure 1).6 
It should be distinguished from perihilar cholangiocarcinoma arising near the biliary 
confluence and distal cholangiocarcinoma arising near the head of the pancreas. Only a 
minority (15%) of ICC patients present with resectable disease at the time of diagnosis. 
Complete surgical resection remains the only option for cure with an estimated median 
survival ranging from 27 to 36 months (Figure 2).5,7–10
Over three-quarters of patients are older than 65 years at initial diagnosis,3 and 
ICC is slightly more common in men.11 ICC is more common in East Asia; in the 
People’s Republic of China, an incidence of 10 per 100,000 persons has been reported, 
while in Thailand, the incidence is 71 per 100,000, higher than for hepatocellular 
carcinoma (HCC).1,12
In general, ICC has similar risk factors to HCC. A correlation with diseases 
causing biliary inflammation and fibrosis, such as primary sclerosing cholangitis and 
primary biliary cirrhosis, has been noted.13,14 Other risk factors for ICC are congenital 
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malformations of the bile duct (ie, choledochal cysts), hepa-
tolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, 
and smoking.13 In East Asia, hepatic parasite infections, in 
particular Opisthorchis viverrini and Clonorchis sinensis, 
are significant risk factors.15,16 The reason for the vast dif-
ference in incidence between the east and west is not fully 
understood, as it cannot be attributed completely to the spread 
of the infectious risk factors.1,12
Histology
ICC mostly develops as a well-differentiated adeno-
carcinoma.17,18 Its formation is frequently caused by muta-
tions of the KRAS oncogene, a protein normally involved 
in the cell proliferation, in combination with the deletion of 
the p53 tumor suppressor gene.19 A critical signaling protein 
downstream of KRAS and p53 mutations is interleukin (IL) 6, 
which is a serum biomarker for ICC.20–22 Further downstream, 
ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, 
have been associated with an aggressive phenotype and 
metastatic disease at diagnosis.23,24
Based on their histological appearance, ICCs can be 
divided into three histological growth types: the mass-forming, 
intraductal infiltrating, and periductal pattern.25,26 The most 
common of these growth patterns is the mass-forming 
pattern, of which the clinical symptoms may be similar to 
HCC as both involve the formation of a mass in the liver.27,28 
On imaging (ie, computed tomography [CT] and magnetic 
resonance imaging [MRI]), these tumors are clearly visible 
and well delineated.26 Mass-forming ICC typically has a 
diameter of 5–10 cm at the time of diagnosis.29,30 Intraductal 
ICC is a slowly growing papillary tumor and has a favorable 
prognosis compared with the other two types.26 On imag-
ing, it is a 1–2 cm mass within the bile duct with proximal 
ductal dilatation. The mass is usually confined to the bile 
duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma 
is characterized by growth along the bile duct without mass 
formation, which radiologically presents as a small lesion 
or diffuse bile duct thickening.33 This type of tumor is a rare 
form of ICC and is commonly seen in combination with mass-
forming ICC.34,35 The different histological appearances of 
cholangiocarcinoma necessitate different surgical strategies, 
since tumors growing along the bile duct (intraductal and 
periductal ICC) often require extrahepatic bile duct resection 
in addition to hepatic resection.26,36
ICC and HCC may occur simultaneously in the same 
patient or even in the same lesion.37,38 Combined HCC and 
ICC tumors mostly follow the more aggressive behavior 
of ICC.37 Because of similar allelic losses in both HCC-like 
and ICC-like cells, these tumors are thought to have a mono-
clonal origin with bidirectional phenotype differentiation.38,39 
In concordance with this hypothesis, a Korean group recently 
suggested that the acquisition of ICC characteristics is a lead-
ing cause of atypically aggressive HCC behavior.40 Further 
research in the fields of imaging and molecular analysis is 
required to improve early diagnosis.38
Staging
The most commonly used classification system to qualify 
advancement and resectability of ICC is the American 
Joint Committee on Cancer (AJCC) TNM staging system, 
currently in its seventh edition, consisting of four stages 
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Figure 1 Types of cholangiocarcinoma.
Note: Adapted by permission from Macmillan Publishers Ltd: Nat Rev Gastroenterol 
Hepatol. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging 
of cholangiocarcinoma. 2011;8(9):512–522. Copyright 2011.134
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Figure 2 Overall survival in a large cohort of intrahepatic cholangiocarcinoma 
patients.
Note: Reprinted from J Am Coll Surg, 221(2), Doussot A, Groot-Koerkamp B, 
wiggers JK, et al., Outcomes after resection of intrahepatic cholangiocarcinoma: 
external validation and comparison of prognostic models, 452–461, Copyright 
(2015), with permission from elsevier.44
Abbreviation: AJCC, American Joint Committee on Cancer Staging.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
11
5.
13
3.
23
3 
on
 1
3-
Ap
r-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1133
intrahepatic cholangiocarcinoma
(Table 1).41 Prior to this edition, there was no separate 
staging system for ICC, and these tumors were classified 
with HCC.42 The T-stage is determined by the number of 
liver tumors, the presence of vascular invasion, and direct 
extrahepatic invasion. The T4 stage is reserved for tumors 
with a periductal growth pattern. N1 indicates the presence 
of regional lymph node metastases, and M1 indicates distant 
metastases.42 Recent research suggests the AJCC staging 
system performs poorly in differentiating between various 
prognoses, with vast inter-patient survival differences within 
TNM stages.43,44 Additional independent prognostic factors 
have been identified to improve staging, including elevated 
serum carbohydrate antigen (CA) 19-9 and carcinoembryonic 
antigen (CEA), lympho(neuro)vascular invasion, and serum 
alkaline phosphatase (ALP).44
A genomic biomarker profile can also help in differentiat-
ing patients with ICC.45–47 A genomic study of 149 patients 
with ICC identified two molecular subgroups, an inflam-
mation and a proliferation group, with distinct clinical out-
comes. The inflammation subclass (40%) showed increased 
activation of inflammation pathways, overexpression of IL-6, 
IL-10, and IL-17, and constitutive activation of immune 
system transcription factor STAT3.47,48 The proliferation 
subclass (60%) showed increased activation of oncogenic 
pathways RAS/MAPK and MET, specific DNA mutations, 
and risk factors for poor clinical outcome.13,48
In a recent meta-analysis, we identified several immu-
nohistochemistry biomarkers for patients with ICC.45 An 
example of a diagnostic and prognostic biomarker is fascin, 
an actin cross-linked protein found in the cell membrane 
of the biliary duct cells.49 The epidermal growth factor 
receptor also plays an important role in prognostics and is a 
potential treatment target.50,51 Mucin 1, cell surface associ-
ated and Mucin 4, cell surface associated are two membrane 
proteins that have been shown to be associated with patient 
prognosis.52–54 Lastly, p27, cyclin-dependent kinase inhibitor 
1B, is a protein involved in the cell cycle, which also has pre-
dictive capabilities in relation to postoperative survival.55–57 In 
addition to these biomarkers, several other biomarkers have 
been shown to have an impact on diagnostics, prognostics, 
and treatment efficacy: HSP27; Akt; HDGF; Mucin 6, cell 
surface-associated; p16; p-4EBP1; S100A4; alpha-SMA; 
keratin 903; and TROP2.45 A composite biomarker profile 
could improve prognosis and guide treatment selection.47
Diagnosis and preoperative workup
The initial diagnosis of ICC is mostly made when the tumor 
is not eligible for resection because of locally advanced or 
metastatic disease.13,14,58 Typically, a very large mass has 
developed in the periphery of the liver with few clinical 
symptoms.19 Most patients present with nonspecific symp-
toms, such as pain in the right upper abdominal quadrant, 
Table 1 American Joint Committee on Cancer TNM classification, seventh edition
TNM stage Definition
T stage
Tx No description of the tumor’s extent is possible because of incomplete information
T0 There is no evidence of a primary tumor
T1 There is a single tumor that has grown into deeper layers of the bile duct wall, but it is still only in the bile duct. 
The cancer has not grown into any blood vessels
T2a There is a single tumor that has grown through the wall of the bile duct and into a blood vessel
T2b There are two or more tumors, which may (or may not) have grown into blood vessels
T3 The cancer has grown into nearby structures such as the intestine, stomach, common bile duct, abdominal wall, 
diaphragm (the thin muscle that separates the chest from the abdomen), or lymph nodes around the portal vein
T4 The cancer is spreading through the liver by growing along the bile ducts
N stage
Nx Nearby (regional) lymph nodes cannot be assessed
N0 The cancer has not spread to nearby lymph nodes
N1 The cancer has spread to nearby lymph nodes
M stage
M0 The cancer has not spread to tissues or organs far away from the bile duct
M1 The cancer has spread to tissues or organs far away from the bile duct
Stage grouping
Stage i T1, N0, M0
Stage ii T2, N0, M0
Stage iii T3, N0, M0
Stage iva T4, N0, M0/any T, N1, M0
Stage ivb Any T, any N, M1
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weight loss, and high serum ALP levels. Some patients pres-
ent with painless jaundice, when the tumor grows towards 
the biliary confluence.14,58 Small ICCs are found in screening 
programs for early detection of HCC.59
Transabdominal ultrasound is often the first imaging 
modality that detects a liver mass with or without dilatation 
of the biliary tract.60 The number of lesions and vascular 
involvement are determined using a dual-phase multi-detector 
CT. Typical appearance of ICC on CT is a hypodense mass 
with irregular margins on unenhanced scans, peripheral rim 
enhancement in the arterial contrast-enhancement phase, 
and progressive contrast uptake in the (portal-)venous and 
delayed contrast-enhancement phase.61 Small ICCs can 
be difficult to distinguish from HCC. Biliary drainage (if 
needed) should be performed after imaging because the 
presence of stents and drains hampers accurate assessment 
of the extent of the tumor.62
Both magnetic resonance cholangiopancreatography 
(MRCP) and positron emission tomography (PET) have a 
good accuracy for diagnosis and assessment of the extent of 
the tumor. MRCP has a diagnostic accuracy of up to 93% 
and is recommended for visualization of the tumor exten-
sion in the ductal system and vascular structures.47,63 Clinical 
utility of PET for diagnosing ICC in the liver when CT or 
MRI has been performed is limited.47 However, preopera-
tive PET scanning may be considered to help rule out occult 
metastatic disease, as PET changes surgical decision making 
in up to 30% of patients.64–66 Despite these imaging modali-
ties, as many as a third of patients with resectable disease on 
imaging have occult metastatic or locally advanced disease 
during diagnostic laparoscopy.67,68 Therefore, better imaging 
is needed to avoid surgery in these patients.14,67,68
Biliary drainage and portal vein 
embolization
ICC may cause biliary obstruction when the tumor grows 
towards the liver hilum. Biliary drainage may be required 
in the preoperative setting with resectable disease and in 
the palliative setting. Biliary drainage aims to improve 
liver function and increase appetite.69 Moreover, preopera-
tive biliary drainage may improve liver regeneration and 
decrease the risk of postoperative liver failure.70,71 The main 
drawback of biliary drainage is colonization of the bile duct 
that often results in cholangitis.72 Patients with a future liver 
remnant of at least 50% should probably undergo a resection 
without preoperative biliary drainage.73,74 Drainage can be 
performed endoscopically or percutaneously. Biliary drain-
age can reduce symptoms and improve quality of life in the 
palliative setting.75,76
A resection of more than 75% of the total liver volume in 
a healthy liver and more than 65% of the total liver volume 
in a compromised liver (eg, due to cirrhosis or fibrosis) is 
an indication of portal vein embolization (PVE).77 PVE 
results in hypertrophy of the future liver remnant by pre-
operatively embolizing the liver that will be resected.77 In a 
total of 1,791 patients with different hepatic tumors, PVE 
had a technical success of 96.1%.77
Surgical management
Resection
Surgical treatment is the only potentially curative treatment 
in patients with ICC. ICC is an aggressive cancer, when 
compared to other primary hepatic neoplasms.4,14,58 A large 
study (n=584) demonstrated that even after curative-intent 
resection, the probability of cure is only about 10%.78 Because 
of the large size as well as intraductal and periductal spread, 
major hepatectomies are required to obtain negative resection 
margins.4 With regard to prognosis, resection is only useful 
when a complete resection (R0) with negative resection 
margins is anticipated. Moreover, the liver remnant should 
be adequate in size and function, with or without prior 
PVE.8,77,79,80 Extrahepatic disease, including lymph node 
metastases beyond the regional basin (N2), is a contraindica-
tion for curative-intent surgery.41 Multifocal ICC is considered 
unresectable by some experts.79–83 Nevertheless, other experts 
report favorable long-term outcomes in selected patients with 
typically two to three lesions, with a 5-year overall survival 
(OS) of 20%.84,85 A 2015 cure model confirms the possibility 
of cure, albeit at a chance of only 4%.78 Recent studies have 
reported favorable outcomes of portal vein reconstructions.86–88 
However, tumor invasion of the main hepatic artery and 
bilateral hepatic artery involvement remain contraindica-
tions for resection in most Western centers. Hepatic artery 
reconstruction is associated with a high risk of postoperative 
mortality as well as poor oncologic outcomes.89,90
A complete resection of ICC involves an (extended) 
hemihepatectomy in most (75%) of patients. Many patients 
(25%) also require a bile duct resection and reconstruc-
tion. Morbidity rates are often more than one in five, and 
mortality rates vary from 1% to 6%.8,9,91 Intraoperative and 
postoperative strategies, such as low central venous pres-
sure, restricted fluid resuscitation, and enhanced recovery 
pathways, have improved recovery and decreased the risk of 
complications.87,88,92 A recent article reviewed perioperative 
management of patients undergoing hepatic resection.93 The 
authors noted that surgeons left an operative drain in almost 
half of patients undergoing liver resection, even though 
most data suggest that routine operative drainage after liver 
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resection (without a biliary anastomosis) is unnecessary and 
should generally be avoided.94–96
Whereas HCC is commonly treated with orthotopic 
liver transplantation (OLT), ICC as an indication for OLT 
is still controversial.97 Historical evidence suggests poor 
outcomes for ICC in single-center studies.98–104 Outcomes of 
OLT for combined HCC and ICC were also predominantly 
unfavorable.98,105 Five-year survival estimates in these studies 
ranged from 10% to 18%, which is clearly inferior to the 
benchmark of OLT of about 70%.97 More recent studies indi-
cate that strictly selected patients might benefit from OLT, 
particularly patients with ICC smaller than 2 cm.106
Systemic chemotherapy
Preoperative chemotherapy
Preoperative chemotherapy (pCT) can be administered for 
multiple purposes, although it is not routinely prescribed due 
to a lack of evidence.107 Neoadjuvant therapy is employed 
to address occult metastatic disease or facilitate resec-
tion. We recently evaluated the role of pCT in a cohort of 
1,057 patients, of whom 62 patients received chemotherapy. 
We found that patients receiving pCT had similar survival 
following curative-intent resection, regardless of more 
advanced disease.107 No regimen is currently proven to have 
effect during the preoperative period. In light of the outcomes 
of the ABC-02 trial, discussed later, a combination of gem-
citabine and cisplatin was offered most often.108
Adjuvant chemotherapy
Adjuvant chemotherapy is aimed at decreasing the chance 
of tumor recurrence.109 Chemotherapy consists of mainly 
nucleoside analogs, most commonly gemcitabine, sometimes 
in combination with cisplatin.109 Systemic therapy is known 
to have a large impact on patient’s quality of life, and form a 
large financial burden. The efficacy of chemotherapy regimens 
in ICC is usually poor, with only a small subgroup benefitting 
significantly in both quality of life and length of survival.16,109 
While a significant portion of the US patients receive che-
motherapy, no randomized trials have been completed.42 
A multicenter phase III trial is currently accruing patients 
to determine the effectiveness of adjuvant gemcitabine and 
cisplatin in patients with biliary cancer (Table 2).
Palliative chemotherapy
A phase III trial, the ABC-02 trial, randomized 410 patients 
with biliary cancer (ie, cholangiocarcinoma and gallbladder 
cancer) and found an improvement in OS of nearly 4 months 
with gemcitabine plus cisplatin compared to gemcitabine 
alone.108 A combined analysis of the ABC-02 trial and the T
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Japanese BT22 trial, conducted in a comparable setting, found 
a hazard ratio of 0.54 (95% confidence interval 0.36–0.81) 
for the subgroup of 108 patients with ICC.110 Gemcitabine 
plus cisplatin has been the standard palliative regimen for 
locally advanced or metastatic ICC since. Best supportive 
care is recommended for patients with a poor performance 
status or a life expectancy of less than 6 months.111–114
Regional treatments
Regional treatments rely on the dual blood supply of the 
liver, where the hepatic artery is mostly responsible for 
the blood supply of tumors, as illustrated by early arterial 
enhancement on imaging.115–117 Hepatic arterial infusion 
(HAI) chemotherapy using a subcutaneous pump has 
been investigated for patients with ICC at Memorial Sloan 
Kettering Cancer Center (MSKCC). It involves continuous 
infusion of floxuridine directly into the hepatic artery. Intra-
arterial delivery allows for a 200-fold higher drug delivery 
to the tumor with little systemic toxicity because of the 95% 
first-pass effect of floxuridine in the liver.5 HAI chemother-
apy has been studied extensively in common malignancies, 
such as colorectal liver metastases.5,118
In a recent study from MSKCC, HAI with floxuridine 
was combined with systemic chemotherapy in patients with 
locally advanced (ie, unresectable without extrahepatic dis-
ease) ICC (n=104).5 Outcomes were compared with locally 
advanced patients receiving systemic chemotherapy alone.5 
Median OS was superior with HAI chemotherapy (30.8 
months vs 18.4 months; P,0.001). Five-year OS was 20% 
in patients who received HAI chemotherapy compared with 
5% in the systemic-only group. In comparison, 5-year OS 
was 0% in the ABC-02 trial.108 Moreover, the partial response 
rate (RECIST criteria) in the HAI chemotherapy group was 
59%, with conversion to resectability in eight of 104 patients 
(13%). Future prospective studies should be conducted in 
order to confirm these results. Currently, a phase II trial is 
recruiting patients for HAI chemotherapy in the adjuvant 
setting (NCT01312857).
Other hepatic artery-based treatments for locally advanced 
ICC include transarterial chemoembolization (TACE) and 
radio-embolization with yttrium-90 (Y-90).115 TACE affects 
the blood flow to the tumor in addition to locally releasing 
cytotoxic agents. It causes ischemic tumor necrosis and facili-
tates intracellular transit of chemotherapeutic agents.115,117 
In a study of 41 prospectively followed patients, one group 
described a median OS of 11.7 months from first treatment, 
after treatment with irinotecan TACE.119 One patient success-
fully underwent resection following TACE.119 Another pro-
spective study reported a median survival of 17.5 months in 
24 patients, with three patients being adequately downstaged 
to undergo resection.120 Despite the encouraging results, no 
phase III trial has been performed.115
Y-90 radio-embolization therapy also aims to improve 
life expectancy in patients with unresectable HCC and 
colorectal liver metastases.115 The technique is based on 
administration of beads filled with the radioactive isotope 
yttrium Y-90 microspheres into the hepatic artery branch 
responsible for the lobes of the liver beset by tumor.121,122 
Prior to treatment, embolization of the nontarget vessels and 
injection of technetium-99mm-labeled macro-aggregated 
albumin is performed, in order to exclude extrahepatic 
accumulation.115,121,122 Several small studies indicate that 
Y-90 is tolerated well in patients with a good performance 
status.123–128 In ICC patients, Y-90 was associated with 
improved survival, when compared with patients undergo-
ing best supportive care only.123–128 Estimates ranged from 9 
months posttreatment in a cohort of 25 Australian patients,127 
to 22 months in a cohort of 33 German patients.126 Random-
ized trials are required to determine the effectiveness of 
Y-90 therapy.
Prognostic models and nomograms
Several prognostic models have been developed in addition 
to the AJCC staging. More accurate prediction of individual 
patient outcome may provide better individual survival 
estimates, as well as improve identification of high-risk 
groups who may benefit from adjuvant therapy.11 While 
the AJCC staging concerns all ICC patients, other models 
pertain only to patients who have undergone a complete 
resection. A Chinese nomogram predicts individual OS 
after resection of ICC (Figure 3).43 Prognostic factors in 
this model included CEA, CA19-9, vascular invasion, 
presence of lymph node metastases, direct invasion and 
local metastases, number of tumors, and tumor diameter. A 
similar model was developed with a multinational dataset 
without tumor markers. Risk factors for survival after resec-
tion were age, number of tumors, tumor diameter, cirrhosis, 
lymph node metastases, and macrovascular invasion.129 The 
Chinese nomogram had superior discrimination at external 
validation.43,44
Other prognostic models were developed for conditional 
survival, accounting for the years that a patient had already 
survived after surgery.84,130,131 Conditional survival was found 
to be the most important prognostic factor, when predicting 
future survival time.84,130,131 OS in this study decreased over 
time to 16% at 8 years, while the 3-year conditional survival 
at 5 years, that is, the chance of surviving to year 8 after 
having survived to year 5, was 65%.84
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Personalized treatments
Personalized treatments for ICC patients could improve the over-
all outcomes, mainly by withholding treatments from patients 
who are unlikely to benefit from surgery or chemotherapy. 
For example, patients with a very poor predicted survival 
after surgery (eg, 3-year OS below 5% based on the Chinese 
nomogram in Figure 3) are unlikely to benefit from surgery. 
Unfortunately, predictive biomarkers for response to systemic 
chemotherapy are not available.45 Future studies should further 
improve prognostic models and identify predictive biomarkers 
to determine the response to chemotherapy.44,132
Future perspectives
ICC is a complex disease, with a dismal prognosis. ICC is typi-
cally diagnosed with metastatic or locally advanced disease. 
Surgery may improve both survival and quality of life, but 
comes with a substantial risk of postoperative morbidity and 
mortality. The benefit of palliative systemic treatment is real 
but small. The merits of (neo)adjuvant therapy still need to be 
explored in phase III trials. Targeted therapies (eg, targeting 
IDH 1 or 2 mutations) are promising but require further evalu-
ation.133 HAI, TACE, and radio-embolization are promising 
locoregional techniques. Appropriate allocation of all locore-
gional and systemic treatments may further improve with 
better knowledge of histopathology and biological behavior.
Ideally, low-cost diagnostic biomarkers could reliably 
detect ICC in patients presenting with vague symptoms of 
the upper abdomen or screened for liver cancer. Furthermore, 
predictive biomarkers are required to determine in advance 
which patients will benefit from chemotherapy.
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